Insights On Drug Development

31. Maximizing Drug Formulation For First-In-Human Trials 8/17/2026

    Discover how integrated formulation, manufacturing, and clinical strategies can accelerate early drug development, reduce timelines, and optimize drug products for clinical success.

32. Navigating An Uncertain Regulatory Environment For mRNA-Based Products 8/17/2026

    mRNA developers face a regulatory gap: as of 2024, neither FDA nor EMA has issued CMC-specific guidelines. Learn how early regulator engagement and CDMO partnerships reduce risk.

33. Exploring 4 Patient-Centric Trends Shaping Today's Biopharma Landscape 8/17/2026

    Patient centricity is reshaping pharma drug development through supply chain resiliency, decentralized trials, and patient-friendly formulations. Learn what these shifts mean for your pipeline strategy.

34. Ophthalmic Drug Delivery: Meeting Modern Challenges With A Next Generation Solution 8/17/2026

    Ophthalmic injectable packaging demands early strategic attention. Learn how silicone oil contamination, particulate limits, and dosing accuracy challenges can derail development programs and what it takes to stay compliant.

35. Cracking Complexity: Leveraging Lessons Learned For Future Bispecific Development 8/14/2026

    The shift from static platforms to adaptive, knowledge-driven development helps biopharma teams manage BsAb complexity, accelerate analytical, purification, and formulation development, and improve IND readiness.

36. Reducing Risks In Biologics Manufacturing Through Predictive Modeling And PAT 8/12/2026

    Complex biologics development increasingly relies on adaptive, knowledge-driven strategies combining platform methods, targeted customization, high-throughput experimentation, and prior knowledge to accelerate IND readiness.

37. Enabling Effective Passive And Active Immune Cell Targeting Strategies 8/10/2026

    Targeted LNPs that bypass the liver and home to the spleen could reshape in vivo CAR T cell manufacturing. See the data behind the approach.

38. Flexibility In Drug Development: From Tactical Response To Strategic Discipline 8/10/2026

    Historically managed through late-stage adjustments, operational adaptability has become a strategic imperative to prevent programs from stalling under real-world pressures.

39. From DNA To IND In 6 Months: Accelerated Development Backed By Experience 8/10/2026

    A rapid, integrated biologics development strategy can achieve IND readiness in as little as six months by combining parallel workflows, early risk mitigation, advanced technologies, robust analytics, and regulatory planning.

40. The Body As A Bioreactor – Delivering The Vision 8/8/2026

    Making the body a bioreactor requires precise delivery to selected cells. See how lipid nanoparticles, manufacturing science, and biology are converging to overcome biological barriers and improve the targeting of advanced therapies.